Tarcha Ziad, Konstantinoff Katerina S, Ince Semra, Fraum Tyler J, Sadowski Elizabeth A, Bhosale Priya R, Derenoncourt Paul-Robert, Zulfiqar Maria, Shetty Anup S, Ponisio Maria R, Mhlanga Joyce C, Itani Malak
From the Mallinckrodt Institute of Radiology, Washington University School of Medicine, 510 S Kingshighway Blvd, St. Louis, MO, 63110-8131 (Z.T., K.S.K., S.I., T.J.F., P.R.D., A.S.S., M.R.P., J.C.M., M.I.); Department of Radiology, Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, 600 Highland Ave, Madison, Wis (E.A.S.); Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Tex (P.R.B.); and Department of Radiology, Mayo Clinic, Scottsdale, Ariz (M.Z.).
Radiographics. 2023 Aug;43(8):e230006. doi: 10.1148/rg.230006.
Fluorine 18-fluorodeoxyglucose (FDG) PET and MRI independently play a valuable role in the management of patients with gynecologic malignancies, particularly endometrial and cervical cancer. The PET/MRI hybrid imaging technique combines the metabolic information obtained from PET with the excellent soft-tissue resolution and anatomic details provided by MRI in a single examination. MRI is the modality of choice for assessment of local tumor extent in the pelvis, whereas PET is used to assess for local-regional spread and distant metastases. The authors discuss the added value of FDG PET/MRI in imaging gynecologic malignancies of the pelvis, with a focus on the role of FDG PET/MRI in diagnosis, staging, assessing treatment response, and characterizing complications. PET/MRI allows better localization and demarcation of the extent of disease, characterization of lesions and involvement of adjacent organs and lymph nodes, and improved differentiation of benign from malignant tissues, as well as detection of the presence of distant metastasis. It also has the advantages of decreased radiation dose and a higher signal-to-noise ratio of a prolonged PET examination of the pelvis contemporaneous with MRI. The authors provide a brief technical overview of PET/MRI, highlight how simultaneously performed PET/MRI can improve stand-alone MRI and PET/CT in gynecologic malignancies, provide an image-rich review to illustrate practical and clinically relevant applications of this imaging technique, and review common pitfalls encountered in clinical practice. RSNA, 2023 Quiz questions for this article are available in the supplemental material.
氟代脱氧葡萄糖(FDG)正电子发射断层显像(PET)和磁共振成像(MRI)在妇科恶性肿瘤患者的管理中各自发挥着重要作用,尤其是在子宫内膜癌和宫颈癌方面。PET/MRI混合成像技术在一次检查中,将PET获得的代谢信息与MRI提供的出色软组织分辨率及解剖细节相结合。MRI是评估盆腔局部肿瘤范围的首选检查方法,而PET则用于评估局部区域扩散和远处转移情况。作者讨论了FDG PET/MRI在盆腔妇科恶性肿瘤成像中的附加价值,重点关注FDG PET/MRI在诊断、分期、评估治疗反应以及鉴别并发症方面的作用。PET/MRI能够更好地定位和界定疾病范围,对病变以及相邻器官和淋巴结的受累情况进行特征描述,提高良性与恶性组织的鉴别能力,同时还能检测远处转移的存在。它还具有降低辐射剂量以及在与MRI同步进行盆腔PET检查时具有更高信噪比的优势。作者提供了PET/MRI的简要技术概述,强调了同步进行的PET/MRI在妇科恶性肿瘤中如何优于单独的MRI和PET/CT,通过丰富的图像展示了该成像技术的实际临床相关应用,并回顾了临床实践中常见的陷阱。RSNA,2023 本文的问答题目可在补充材料中获取。